Health Economics›Thyroid cancer medullary›Locally advanced or metastatic disease targeted therapy-naive

Locally advanced or metastatic disease targeted therapy-naive

Thyroid cancer medullary · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cabozantinib monotherapy Variant #01	—	R 90 983	28d	16.8 mo	—	19	R 1 728 674 PFS proxy	1
Sorafenib monotherapy Variant #04	—	R 37 339	28d	~10.8 mo	—	~12	~R 448 066 PFS proxy · indirect	1
Selpercatinib monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	1
Vandetanib monotherapy Variant #01 Partial	—	—	28d	16.8 mo	—	19	—	2

4 of 4 regimens shown